Erlotinib [25 mg, 100 mg, 150 mg Film-Coated Tablet] for the treatment of locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) with activating Epidermal Growth Factor Receptor (EGFR) mutations

HTA Council Recommendation (as of 12 March 2026) As a final recommendation, the HTA Council recommends the government financing of erlotinib (25 mg, 100 mg, and 150 mg film-coated tablet) for first-line therapy of patients with EGFR-positive advanced or metastatic NSCLC. Erlotinib is recommended for EGFR exon 19 deletion or exon 21 L858R mutation. Additionally, continue reading : Erlotinib [25 mg, 100 mg, 150 mg Film-Coated Tablet] for the treatment of locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) with activating Epidermal Growth Factor Receptor (EGFR) mutations

Gefitinib [250 mg film-coated tablet] for the treatment of locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) with activating Epidermal Growth Factor Receptor (EGFR) mutations

HTA Council Recommendation (as of 12 March 2026) As a final recommendation, the HTA Council recommends the government financing of gefitinib [250 mg film-coated tablet] for first-line therapy of patients with EGFR-positive advanced or metastatic NSCLC. Gefitinib is recommended for EGFR exon 19 deletion or exon 21 L858R mutation. Additionally, it is an option for continue reading : Gefitinib [250 mg film-coated tablet] for the treatment of locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) with activating Epidermal Growth Factor Receptor (EGFR) mutations

Afatinib [20 mg, 30 mg, and 40 mg film-coated tablet] for the treatment of locally advanced or metastatic EGFR-positive Non-Small Cell Lung Cancer (NSCLC)

HTA Council Recommendation (as of 12 March 2026) As a final recommendation, the HTA Council recommends the government financing Afatinib (20 mg, 30 mg, and 40 mg film-coated tablet) for first-line therapy of patients with EGFR-positive advanced or metastatic NSCLC. Afatinib is recommended for EGFR exon 19 deletion or exon 21 L858R mutation. Additionally, it continue reading : Afatinib [20 mg, 30 mg, and 40 mg film-coated tablet] for the treatment of locally advanced or metastatic EGFR-positive Non-Small Cell Lung Cancer (NSCLC)

Epidermal Growth Factor (EGFR) tests [Tissue-based EGFR PCR Mutation Test] for diagnosis of EGFR mutations in patients with NSCLC

HTA Council Recommendation (as of 18 March 2026) As final recommendation, the HTA Council recommends tissue-based EGFR PCR Mutation Test for the diagnosis of EGFR mutations in patients with non-squamous NSCLC; and, for patients diagnosed with squamous NSCLC aged <50 years old, regardless of smoking history, for government financing. The Council further recommends adherence to the recommended continue reading : Epidermal Growth Factor (EGFR) tests [Tissue-based EGFR PCR Mutation Test] for diagnosis of EGFR mutations in patients with NSCLC